Nanocomposites-Based Targeted Oral Drug Delivery Systems with Infliximab in a Murine Colitis Model

Jung Min Kim
Yonsei University College of Medicine

Da Hye Kim
Yonsei University College of Medicine

Hyo Jeong Park
Sejong University

Hyun Woo Ma
Yonsei University College of Medicine

I Seul Park
Yonsei University College of Medicine

Mi Jeong Son
Yonsei University College of Medicine

So Youn Ro
Sejong University

SeokMann Hong
Sejong University

Hyo Kyung Han
Dongguk University

Soo Jeong Lim
Sejong University

Seung Won Kim
Yonsei University College of Medicine

Jae Hee Cheon  (geniushee@yuhs.ac)
Yonsei University College of Medicine

Research

Keywords: Inflammatory bowel disease, Infliximab, Nanocomposite carrier, Oral delivery system

DOI: https://doi.org/10.21203/rs.3.rs-32688/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Infliximab (IFX), a TNF-α blocking chimeric monoclonal antibody, induces clinical response and mucosal healing in patients with inflammatory bowel disease (IBD). However, systemic administration of this agent causes unwanted side effects. Oral delivery of antibody therapeutics might be an effective treatment strategy for IBD compared to intravenous administration. We developed a colon-specific drug delivery system for the oral administration of IFX using ternary nanocomposite carriers. Nanocomposite carriers consisting of liposomes, aminoclay-coated liposomes (AC-L), Eudragit S100 AC-L (EAC-L) or those carrying IFX (IFX-L, AC-IFX-L, and EAC-IFX-L) were orally administered to mice with dextran sulfate sodium-induced colitis. We evaluated the effects of nanocomposite carriers on lymphocytes and monocytes in peripheral blood mononuclear cells (PBMC) of IBD patients. We studied the therapeutic effects of the nanocomposites themselves and nanocomposites with IFX at target sites in vivo and in vitro. All three carriers had a high encapsulation efficiency, narrow size distribution, and minimal systemic exposure. There was a higher interaction between nanocomposite carriers and monocytes compared to lymphocytes in the PBMC of IBD patients. Orally administered nanocomposite carriers targeted to inflamed colitis minimized systemic exposure. All IFX delivery formulations with nanocomposite carriers had a significantly less colitis-induced body weight loss, colon shortening and histomorphological score, compared to the DSS-treated group. AC-IFX-L and EAC-IFX-L groups showed significantly higher improvement of the disease activity index, compared to the DSS-treated group. In addition, AC-IFX-L and EAC-IFX-L alleviated pro-inflammatory cytokine expressions (TNfa, Il1b, and Il17). We present orally administered antibody delivery systems which improved efficacy in murine colitis while reducing systemic exposure. These oral delivery systems suggest a promising therapeutic approach for treating IBD.

Background

Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition of the gastrointestinal tract. Cytokines are essential mediators of IBD pathophysiology and tumor necrosis factor (TNF)-α has a crucial function in the initiation and perpetuation of IBD [1]. TNF-α alters epithelial integrity, disrupts barrier function, and promotes the breakdown of intestinal homeostasis [2]. Moreover, the binding of TNF-α to the TNF receptor is associated with the prevention of apoptosis and prolongation of pro-inflammatory T cell survival in IBD [3]. Increased blood monocyte recruitment into the gut of IBD patients generates macrophages that leads to the secretion of inflammatory cytokines such as TNF, IL-6, and IL-23 [4].

Therapeutic monoclonal antibodies against TNF-α are used to treat IBD [5, 6]. These monoclonal antibodies have some advantages in terms of stability, bioavailability, and superior antigen targeting affinity. Infliximab (IFX) is a mouse/human chimeric monoclonal immunoglobulin G1 (IgG1) antibody against TNF-α. It directly neutralizes the biological activity of TNF-α. IFX is more effective at inducing clinical remission of IBD and mucosal healing than conventional drugs [7, 8]. However, IFX has infrequent but serious side effects such as infectious complications, autoimmune responses, and malignancy [9-11].
Furthermore, repeated intravenous administration of IFX is costly and associated with poor compliance [12]. Ideally, an anti-TNF antibody therapy for IBD would be delivered directly to the intestinal inflammatory sites, avoiding systemic exposure and immunosuppression.

Liposome is an attractive drug carrier; it has high biocompatibility and biodegradability, low toxicity, and non-immunogenic properties. Liposomes are mainly composed of phospholipids, and the release rate depends on the number of phospholipid bilayers [13]. Phospholipid barriers block the action of enzymes, acids, and free radicals, and protect the cargo from breaking down until it reaches the target site and is released. Specific pH range-triggered release and liposome encapsulation delays drug release specific to the gastrointestinal tract, which enhances therapeutic efficiency. Liposome-encapsulated IFX was observed to have therapeutic efficacy in autoimmune uveoretinitis [14]. In addition, liposomes provide better recovery of impaired epithelial barrier function than control in a dose-dependent manner [15]. Because ideal colon-specific delivery systems require the prevention of premature drug release, the properties of the liposome surface coating material encapsulating the anti-TNF-α agent are important because they affect the efficiency of the delivery system. Ideal colon-specific delivery systems require the prevention of premature drug release before reaching the target site.

Aminoclay is a synthesized organoclay 3-aminopropyl functionalized magnesium phyllosilicate. Oral delivery systems designed with aminoclay complex enhance the bioavailability of a low solubility/high permeability drug [16]. Indeed, aminoclay is less cytotoxic and can reduce cargo dosages, while enhancing delivery efficiency and allowing for the loading of macromolecules [17]. However, the therapeutic effect or improvement of impaired barrier function in IBD via aminoclay-anti-TNF-α complex has not yet been reported.

Eudragit (methacrylic acid copolymer) is a pH-sensitive coating polymer [18]. Eudragit with prednisolone was reported to efficiently degrade and deliver drugs only at colon-specific pH both in vivo and in vitro, thus minimizing drug side effects [19]. In addition, Eudragit was able to deliver 5-aminosalicylic acids to the target site with minimal systemic absorption [20]. Furthermore, the Eudragit coating system has a higher mucosa-adhesive ability than control coating systems [21]. However, no studies of Eudragit encapsulating anti-TNF-α have been reported in vivo or in vitro.

Therefore, the aim of the current study was to evaluate the effectiveness and safety of new oral colon-targeted IFX delivery systems using ternary nanocomposite carriers in a murine colitis model.

**Results**

**Characterization and gastrointestinal stability of nanocomposite carriers**

Transmission electron microscopy images showed that BSA-FITC coated with BSA-L, AC-BSA-L, and EAC-BSA-L were spherical and surrounded the inner aqueous core containing BSA-FITC (Fig. 1a). Particle size and zeta potential analysis using dynamic light scattering showed a gradual increase in particle sizes (360, 396, and 406 nm in BSA-L, AC-BSA-L, and EAC-BSA-L, respectively) and reversal of zeta potential
values (-79.9, +12.6, and -55.4 mV in BSA-L, AC-BSA-L, and EAC-BSA-L, respectively) in the layer-by-layer coating. The net negative surface charge of BSA-L appeared to promote the alternating deposition of positively charged aminoclays through electrostatic interactions. The positively charged surface of AC-BSA-L allowed the deposition of anionic Eudragit S100, resulting in layer-by-layer coated EAC-BSA-L. Entrapped BSA-FITC concentrations of nanocomposites were 769 ± 14 μg/mL (BSA-L), 498 ± 85 μg/mL (AC-BSA-L), and 338 ± 15 μg/mL (EAC-BSA-L). A gradual decrease in entrapped protein concentration by coating was caused by the leakage of entrapped proteins during the layering process.

Nano-sized IFX-entrapped liposomes gradually increase in size (244, 222, and 426 nm in IFX-L, AC-IFX-L, and EAC-IFX-L, respectively) and zeta potential values were reversed (-54.8, +2.6, and -31.5 mV in IFX-L, AC-IFX-L, and EAC-BSA-L, respectively) (Fig. 1b). The decrease in the concentration of nanocomposites with BSA, the entrapped concentrations of nanocomposites also decreased (2,888 ± 236, 1,480 ± 71, and 686 ± 63 μg/mL in IFX-L, AC-IFX-L, and EAC-IFX-L, respectively). Compared with BSA, IFX had a higher loading concentration, which may be due to the difference between hydrophilic and hydrophobic aa domains. IFX contains more hydrophobic parts that are more compatible with phospholipid membranes than BSA, resulting in their entrapment at higher concentrations. Collectively, these observed structural properties confirmed the successful formation of the antibody drug delivery nanocomposites of liposomes, aminoclay, and Eudragit S100.

We next assessed the physical stability of BSA-entrapping nanocomposite carriers under simulated gastrointestinal conditions by using the dialysis. The protein integrity profile of free BSA before and after exposure to simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) is shown in Supplementary Figure 1. When free BSA solution was incubated in SGF without pepsin supplementation, no significant change in the BSA-corresponding protein band was observed, indicating the high protein stability of BSA under the experimental conditions (Fig. S1a). The complete loss of the BSA band was observed after 1-min incubation in SGF supplemented with pepsin, indicating a rapid protein degradation induced by enzymatic action (Fig. S1b). In SIF supplemented with pancreatin, protein degradation was slower than control, but occurred in a time-dependent manner (Fig. S1c). The decrease in the protein band of the BSA obtained from nanocomposite carriers (BSA-L, AC-BSA-L, and EAC-BSA-L) was much less and slower in both SGF and SIF (supplemented with pepsin or pancreatin), compared to free BSA solution (Fig. S1d, e).

Particle size changes and protein release profiles from the three nanocomposite carriers were also examined in PBS, SGF, or SIF (Fig. 1c). Eudragit S-100 is a pH-sensitive formulation that decomposes above pH 7, and because Eudragit-coating does not peel off in PBS and SIF, the size of the nanocomposite carriers was unchanged. All of the tested nano-formulations were observed to have delayed and reduced drug release (Fig. 1d). In particular, EAC-BSA-L showed minimal drug release in SIF for 2 h, suggesting its superior ability to retard premature release of the protein drug. EAC-BSA-L increased in size as soon as it was added to SGF. However, because there was no change in size until 8 h and there was no change of protein structure in circular dichroism data, EAC-BSA-L exists as a weak aggregate between particles under acidic conditions, but there was no change in the structure of the nanocomposite carriers. In PBS incubation, the spectra of free BSA and the other three nanocomposite-
encapsulated BSAs were different (Fig. 1e). This may be due to the separation of the liposomes by adding SDS just before the circular dichroism measurement to isolate the BSA inside the liposome. Collectively, the α-helix structure of free BSA was broken under SGF (pepsin +) for 1 h. Whereas the structure of BSA with nanocomposite carriers was much better maintained than free BSA group, especially to BSA encapsulated in EAC-BSA-L remained nearly intact.

These results indicate the successful fabrication of drug delivery nanocomposite carriers with the ability to safely and slowly release encapsulated cargo under gastric and intestinal conditions.

**Targeting ability of nanocomposite carriers**

To confirm targeting ability, we performed an *in vivo* drug targeting study using Cy7-labeled nanocomposite carriers in mice with DSS-induced colitis fed a purified diet AIN-76A (Table S1). At 7 h post-administration of the Cy7 labeled delivery carriers, fluorescence imaging showed stronger Cy7 fluorescence signal in the colon and a significant but weaker Cy7 fluorescence signal in the small intestine (Fig. 2a, b). In the cecum and colon without colitis, EAC-L group exhibited higher fluorescence signals. In contrast, other organs (heart, lung, liver, spleen, pancreas, and kidney) did not show significant Cy7 fluorescence signals (Fig. 2c). The average radiant efficiency of all nanocomposite carriers in the inflamed colon was increased. The AC-L treated mice with the inflamed colon had higher values than DSS only group and mice treated with EAC-L without colitis had higher values than control groups (Fig. 2d). These results of the biodistribution study using Cy-7 indicate no significant systemic exposure of nanocomposite carriers when orally administered to target the inflamed colon.

**Nanocomposite carriers enhance the anti-inflammatory capacity of intestinal macrophages**

The potent anti-inflammatory capacity of T cells and monocytes have a crucial function in colitis. Dysregulation of CD4 T helper cells and their signature cytokines can contribute to IBD pathogenesis [22]. TNF-α secretion is significantly increased by inflamed lamina propria monocytes in IBD patients, and the clinical severity of IBD and serum TNF-α level are correlated [23, 24]. To evaluate the effects of nanocomposite carriers (L-FITC, AC-L-FITC, and EAC-L-FITC) on lymphocytes (CD3⁺CD4⁺ cells) and monocytes (CD11b⁺ cells) in PBMCs of IBD patients, we observed a subset of CD3⁺CD4⁺ T cells and CD11b⁺ monocytes (Fig. 3a). The mean fluorescence intensity (MFI) values of nanocomposite carriers in lymphocytes were between 1,000 and 3,000, and those of nanocomposite carriers in monocytes were between 3,000 and 15,000. Lymphocytes of patients with ulcerative colitis had significantly higher MFI values in the all nanocomposite carrier groups compared to the BSA-FITC group, whereas monocytes in ulcerative colitis patients did not differ significantly from those of BSA-FITC group (Fig. 3b). The EAC-L-FITC group had significantly higher MFI values in the lymphocytes and monocytes of patients with Crohn's disease compared to the BSA-FITC group. AC-L-FITC group had significantly a higher MFI value in lymphocytes of Crohn's disease patients than BSA-FITC group, but there was no difference in monocytes. These results suggest that nanocomposite carriers may have a higher absorption into monocytes than lymphocytes, and that absorption into lymphocytes show a significant difference between carriers.
IFX-L, AC-IFX-L, and EAC-IFX-L delivered IFX to targeted inflamed colon and resulted in therapeutic effects

We examined the therapeutic effects of L, AC-L, EAC-L, PO-IFX, and IP-IFX (10 mg/kg) in mice with DSS-induced colitis (Fig. S2a). Our results showed that liposome-treated mice had a significantly less colitis-induced body weight loss and colon shortening (Fig. S2b, c). In addition, mice treated via intraperitoneal injection of IFX had a significant reduction of colon shortening (Fig. S2c). These results were further supported by DAI findings (Fig. S2d). In the PAS-stained colon tissues, mice treated with liposomes (L group) or IFX via intraperitoneal injection (IP-IFX group) had less colon tissue damage and inflammatory cell infiltration than those treated with other nanocomposite carriers or control group (Fig. S2e). Histomorphological scores were significantly lower in L and IP-IFX groups compared to the DSS inflammation group, whereas goblet cell scores were not significantly different between the treatment groups. These results might suggest that drug delivery via liposome encapsulation is superior to other nanocomposite carriers in terms of its anti-inflammatory effects.

To test the therapeutic effects of nanocomposite carriers loaded with IFX, mice were orally administrated PBS, IFX-L, AC-IFX-L, EAC-IFX-L, or IFX daily (10 mg/kg, PO) from day 0 to day 8 (total 9 days). Colitis was induced by administering 1.5% DSS through drinking water for 7 days (Fig. 4a). IFX-L, AC-IFX-L, and EAC-IFX-L groups resulted in significantly less weight change, compared to the DSS-treated group (Fig. 4b). All IFX delivery formulations with nanocomposite carriers had a significantly greater therapeutic effect in terms of colon length reduction and histopathological inflammatory cell infiltration, compared to the DSS-treated group (Fig. 4c, e). There was no significant difference in colon shortening between the nanocomposite carriers themselves and the IFX encapsulated by nanocomposite carriers. There was a significantly higher improvement of DAI in the AC-IFX-L and EAC-IFX-L groups, compared to the DSS-treated group (Fig. 4d). Interestingly, EAC-IFX-L showed lower DAI value than EAC-L. All IFX delivery formulations with nanocomposite carriers showed significantly lower histomorphological scores than the DSS-treated group. The IFX-L group showed a higher goblet cell score than the DSS-treated group. AC-IFX-L group showed lower histomorphological scores and higher goblet cell scores than AC-L group. These results suggest that the conjugation of IFX to nanocomposite carriers preserves IFX function which successfully targets the colitis site.

Anti-inflammatory effects of nanocomposite carriers loaded with IFX

We used western blotting to investigate the effects of IFX delivery formulations on the protein expression of TNF-α and IL-1β. Induction of inflammation by DSS increased the expression of TNF-α and IL-1β, whereas protein expression in the EAC-IFX-L group was significantly decreased (Fig. 5a). The expression of TNF-α in the AC-IFX-L group was also significantly decreased, compared to the DSS only group.

As an indicator of therapeutic effect of the IFX delivery formulation against inflammation, TNF-α expression in serum extracted from mice was measured by ELISA. In the all IFX delivery formulations with nanocomposite carrier groups, the expression levels of TNF-α were significantly decreased compared to the DSS-treated control group (Fig. 5b).
Inflammation-related factors (IL1b, TNFa, IL6, IL17, and INOS) were analyzed at the mRNA level in the DSS colitis colon after receiving IFX delivery formulation (Fig. 5c). The IFX-L group exhibited significantly lower level of TNFa and IL17 compared to the DSS-treated control group. Interestingly, the levels of IL1b and IL17, as well as TNFa, were reduced in the AC-IFX-L and EAC-IFX-L groups. All drug delivery formulations showed no significant decrease in INOS and IL6 compared to the DSS-treated group. However, there was a larger fold change in mRNA levels of inflammation-related factors in the direct oral administration of IFX group without carriers than via drug delivery formulations, but this was no statistically significant difference (Fig. S3). Collectively, these results suggest that the three drug delivery formulations with entrapped IFX successfully targeted TNFa in the inflamed colon and had an anti-inflammatory effect in a DSS-induced colitis model.

**Discussion**

Colon-targeted oral drug delivery systems are quite an attractive therapeutic strategy for the treatment of diseases affecting the colon, such as IBD [25, 26]. An ideal colon-specific delivery system maintains the maximum target-specific concentration of an entrapped drug, while minimizing systemic exposure by preventing premature drug release. The colon, a suitable delivery target site for proteinaceous drugs, has relatively limited proteolytic activity compared to other parts of the gastrointestinal tract. The residence time of drugs in the colon is also relatively longer than that of other sites [27, 28]. In this regard, the properties of surface coating materials and their interactions with liposomes are important determinants of the effects of liposome drug carriers targeting the colon. The efficiency of orally administered drugs delivered to the colon is improved by the polymer coating liposome formulation via pH-dependent release and mucosa-adhesive properties. In addition, phosphatidylcholine, a major component of the gastrointestinal membrane and liposome, reduces the inflammatory response and induces remission in patients with ulcerative colitis [29]. Aminoclay is an excellent material for improving the bioavailability of poorly water-soluble drugs. The drug-clay complexes can regulate drug release properties by interacting with negatively charged drug molecules in water. Indeed, various delivery systems have been developed using Eudragit-coated liposome or aminoclay as efficient and versatile biocompatible carriers [30, 31]. The charges of AC-L are made positive by the amino groups (-NH\textsubscript{3}) of aminoclay and the charges of the anionic polymer nanoparticles of EAC-L are negative because of the carbonyl groups on the polymeric chain extremities. Overall, the results of the current study showed that nanocomposite carriers can serve as efficient oral delivery carriers in the treatment of IBD.

In this study, the degradation of nanocomposites entrapped with BSA was not significant in SGF and SIF, and the release rate of BSA in PBS and SIF was lower than that of free BSA. Normal pH ranges from 5.9 in the proximal colon to 6.1 in the distal colon, However, colon pH values in IBD patients vary significantly from pH 4.8 to 7.3 [32, 33]. Because bile salts and digestive enzymes (pancreatin) have a synergistic effect on the breakdown of liposome membranes in SIF, drug release rates increase in SIF compared to SGF [25, 34]. However, in this study, the difference in diameter change between SIF and SGF was minimal. Liposomes are less susceptible to pepsin alone and stable to pancreatin at neutral pH without bile salts.
The reason that results of the current study differ from previous studies may be because we did not mix bile salts with digestive enzymes that could break the integrity of liposome by solubilizing the membrane and forming temporary pores. However, the current study showed that the nanocomposite carriers are stable even at different pH changes, such as in the stomach or small intestine, and can reach the colon by maintaining stable drug concentrations for a long time. The stability of BSA was analyzed by circular dichroism spectroscopy which indicated that the α-helix structure of free BSA was broken after 1 h under SGF (pepsin +). However, the BSA in nanocomposite carriers retained a much better structure than free BSA, especially in EAC-L was included.

IBD patients are characterized by altered expression of tight junction proteins and loss of barrier integrity [36, 37]. In addition, TNF-α, a pathological cytokine, increases epithelial permeability through changes in tight junction function and structure. In this study, we orally administered IFX targeting the colon using liposomes, aminoclay, and Eudragit S100-based nanocomposite carriers. In previous studies, in vivo image analysis by confocal microscopy confirmed the effective intracellular distribution of fluorescently labeled nanocomposite carriers in the colon [38, 39]. The expression of each macrophage marker gene and the accumulation of liposomes showed a significant positive correlation, and liposomes enhanced the accumulation of drug candidates through macrophages in damaged colon tissues [40]. In addition, the fluorescence intensity of fluorescence-labeled liposomes is closely related to the expression levels of the macrophage marker. This indicates that the absorption mechanism of the liposomes is related to the phagocytic property of macrophages [40]. Furthermore, a previous study of nanocomposite carriers using aminoclay and Eudragit in LPS-stimulated RAW 264.7 cells, found no toxicity to macrophages [39]. The results of these publications, taken together with those of the current study, indicate that these nanocomposites may be good candidates as carriers for oral drug delivery (Fig. 6).

Since Eudragit degrades below pH 6.8 and the gastrointestinal tract in mice is shorter than that of humans, the therapeutic effects of EAC-L and EAC-IFX-L require further study. Importantly, our work provides additional insight into the development of orally administered nanocomposite carriers for the treatment of colitis. In addition, our method of coating IFX has already proven to be an effective approach in treating IBD and has the potential to be used in personalized medicine to provide a tailored oral delivery carrier because it reaches the colon and targets macrophages with unique biocompatibility and biodegradability.

The increased secretion of TNF-α and IL1β in the colonic lamina propria has an important function in the development of IBD. Patients with ulcerative colitis have higher baseline levels of IL1β and TNF-α than in patients with Crohn's disease [41]. IFX treatment increases the apoptosis of T lymphocytes in the intestinal mucosa [42]. The expression of IL17 is increased in the intestinal mucosa and serum of IBD patients [43]. The reduction of IL17 expression in the intestinal mucosa of IBD patients is closely associated with endoscopic response and mucosal healing after IFX treatment [44]. Our results indicate that drug delivery formulations significantly increased MFI values for lymphocytes in patients with ulcerative colitis, while the mRNA expression of Tnfa, Il1b, and Il17 was significantly decreased. Il1b and Il17, which are involved in the pathogenesis of IBD due to innate lymphoid cells and CD4+ Th17 cells,
were significantly decreased in the EAC-IFX-L group [45, 46]. Therefore, although our EAC-L data suggest that it is selectively taken by macrophages to improve DSS-induced mouse colitis, further studies on the molecular mechanisms regulating macrophage function are necessary. Our results indicate that carriers coated with liposomes alone and aminoclay-coated liposomes also contributed to anti-inflammatory responses. Further studies on the regulation of inflammatory cytokines by the carriers themselves are required to confirm their anti-inflammatory effects and those of liposomes.

Conclusion

All three nanocomposite carriers loaded with IFX were prepared with narrow size distribution and high encapsulation efficiency. Theses nanocomposite carriers loaded with IFX provide a colon-specific anti-inflammatory effect without adversely affecting systemic homeostasis. Oral drug delivery by EAC-L may be a novel means of transporting large molecule drugs to the intestines in a non-cytotoxic way, to stimulate CD4$^+$ T cells as well as macrophages. Furthermore, the unique propensity of EAC-L enhances anti-inflammatory responses of intestinal macrophages and provides attractive strategies for preventing or treating autoimmune diseases. All the three nanocomposite carriers loaded with IFX had better colitis improvement than the control group. In addition, IFX treatment by AC-IFX-L and EAC-IFX-L-based nanocomposites not only showed a significant anti-inflammatory effect, but also remarkably decreased TNF-α level in a DSS-induced mouse colitis model. This suggests that these oral anti-TNF delivery systems be a promising therapeutic approach for treating IBD.

Methods

Reagents and Materials

1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dimyristoyl-sn-glycerol-3-phosphoryl-glycerol sodium salt (DMPG) were purchased from Avanti Polar Lipid Inc. (Alabaster, AL, USA). Cholesterol (Chol), α-tocopherol, bovine serum albumin (BSA) fluorescein isothiocyanate conjugate (FITC-BSA), ammonium persulfate, pepsin, pancreatin, and Remicade® (IFX) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cy™7 Mono NHS Ester was purchased from GE Healthcare (Little Chalfont, Buckinghamshire, UK). BCA Protein Assay Kit and PageRuler Prestained Protein Ladders were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Sodium dodecyl sulfate (SDS) was purchased from Kracker Scientific (NY, USA). Coomassie-brilliant blue R-250 staining solution, 30% acrylamide/Bis solution (29:1), TEMED, 4× Laemmli sample buffer, 1.5 M Tris-HCl buffer and 0.5 M Tris-HCl buffer were purchased from Bio-Rad Laboratories (Hercules, CA, USA.). Magnesium chloride hexahydrate (98%) and other inorganic salts were purchased from Junsei Chemical Co. (Tokyo, Japan). Eudragit® S100 was kindly donated by Evonik Korea (Seoul, Korea).

Preparation of liposomes
DMPC, Chol, DMPG, and α-tocopherol were mixed at a molar ratio of 26:10:2:2 in tertiary butyl alcohol. The mixtures were frozen at -80°C overnight followed by freeze-drying (EYELA FDU-1200, Tokyo, Japan) for 24 h. The lipid cakes (total 40 μmol of lipid mixture) obtained were hydrated with 1 mL of IFX solution, which was obtained by dissolving Remicade powder in distilled water (10 mg/mL), or FITC-BSA solution in phosphate-buffered saline (pH 7.4). The hydrated liposome dispersions were vortexed and sonicated for 1 h at 24°C of DMPC by using an ultrasonic cleaning bath (Branson®, 3510-DTH Ultrasonic Cleaner, Danbury, CT, USA). To obtain a liposomal dispersion with increased homogeneity and reduced particle size, additional sonication was carried out by using a cell disruptor (Bioruptor®, UCD-200T, Cosmo Bio Co., Tokyo, Japan) as previously described [47]. Liposome dispersions were then subjected to freeze-thawing for five cycles of 5 min incubation at -180°C and 15 min incubation at 37°C to improve the protein encapsulation. To remove non-encapsulated proteins, liposomes were collected by centrifugation at 43,000 × g for 1 h at 4°C. The resulting pellets were re-suspended in the original volume of phosphate-buffered saline (PBS). The prepared liposomes were stored at 4°C until use.

**Coating of liposomes**

The 3-aminopropyl-functionalized magnesium phyllosilicate (aminoclay) was synthesized by following a method described previously.[39] Before coating, the bulk aminoclay powder was dispersed in water, followed by ultrasonication for 10 min, for the exfoliation of the aminoclay. Aminoclay-coated liposomes (AC-L) were obtained by spontaneous assembly of positively charged aminoclay on negatively charged liposomal surfaces. Briefly, equal volumes of liposome dispersions pre-diluted with distilled water to give a lipid concentration at 10 mg/mL were added drop-wise to exfoliated aminoclay dispersion (10 mg/mL) to give a lipid/clay weight ratio of 1:1. The mixture was incubated at 25°C for 30 min with stirring and then centrifuged at 15,000 × g for 7 min at 4°C. The resulting aminoclay-liposome pellets were re-suspended in 1 mL of PBS.

For further coating of clay-liposomes with Eudragit S-100, an equal volume of clay-liposome dispersions pre-diluted to a concentration of 2.5 mg lipid per mL was added drop-wise to 0.1% Eudragit S100 solution in PBS. The mixture was incubated at 4°C for 30 min with stirring and then centrifuged at 15,000 × g for 7 min at 4°C. The resultant Eudragit S100-coated aminoclay-liposome (EAC-L) pellets were re-dispersed in the original volume of PBS.

**Physicochemical characterization of liposomes**

The mean particle size and polydispersity index of nanocomposite carriers were measured by dynamic light scattering using a fiber-optics particle analyzer (FPAR-1000, Otsuka Electronics, Osaka, Japan) as described in our earlier studies.[15] Particle size analysis data were assessed using the CONTIN program provided by the manufacturer. Zeta potential (the electrical potential at the shear plane of the nanoparticle) was measured using a Zetasizer Nano ZSP (Malvern, UK). Samples were diluted 50-fold with deionized water before measuring to reach the analytical measurement range. Default instrument settings and automatic analysis were used for all measurements. Each measurement was carried out in duplicate.
The diameter and morphology of liposomes were imaged by negative-stain transmission electron microscopy. Liposome samples were 50-fold diluted with PBS solution and dropped on a 200-mesh copper grid coated with carbon and negatively stained with 2% uranyl acetate for 1 min. Excess stain was removed and the samples were allowed to air-dry completely. Dried samples were examined using a Tecnai G2 Spirit (FEI Company, Hillsboro, OR, USA) operating at 120 keV.

The encapsulated concentration of IFX and FITC-BSA were determined by BCA protein assay or by measuring the fluorescence of FITC (excitation 490 nm, emission 525 nm) with a fluorescence spectrometer (FS-2, Scinco Ltd., Seoul, Korea) after disrupting the liposome dispersions with an equal volume of 10% SDS (fluorescence assay) or ethanol (BCA assay). Standard curves pre-constructed with serial dilutions of FITC-BSA with ethanol were used to convert fluorescence to FITC-BSA concentration. The stability of BSA in the nanocomposite carriers was investigated using circular dichroism spectroscopy. Gastrointestinal stability of liposomes and protein stability analysis are described in the Supplementary Information.

Animal studies

Experimental animals

Eight-week-old C57BL/6 mice were kept under standard conditions at 21-22°C under 12 h light/dark cycle and allowed to acclimate for a week before starting the experiment. Body weight and physical activity were monitored daily.

Distribution of nanocomposite carriers in dextran sulfate sodium (DSS) colitis mice

To assess the biodistribution of nanocomposite carriers after oral administration, Cyanine-7 (Cy7)-labeled nanocomposite carriers were prepared. Briefly, two μg of Cy7 was dissolved with 40 μmol of DMPC:Chol:DMPG:α-tocopherol (26:10:2:2) mixture in tertiary butyl alcohol. The liposomes were prepared from the mixture as described above, except that the un-entrapped Cy7 was separated from the liposomes by dialysis. Each liposome dispersion was adjusted to 0.44 μg/mL before oral administration.

Colitis was induced in mice by oral administration of 1.5% (wt/vol) DSS (36-50 KD molecular weight, MP Biomedicals, Solon, OH, USA) for 5 days in drinking water. After fasting for 12 h, Cy7.0-L, Cy7-AC-L, and Cy7-EAC-L were orally administered to mice with DSS-induced colitis at a dose of 20 mg/kg in a volume of 100 μL PBS. Control mice maintained normal drinking water for 5 days and then Cy7.0-EAC-L was administrated orally at the same dose. Mice were sacrificed 7 h after administration of Cy7.0-labeled nanocomposite carriers. Cy7.0-labeled nanocomposite carriers were visualized (Cy7: excitation 750 nm, emission 773 nm) and analyzed by using an in vivo image analyzer (Caliper IVIS Lumina II, Caliper Life Science, USA).

DSS-induced colitis and therapeutic effect of nanocomposite carriers
To test the therapeutic effect of nanocomposite carriers, colitis was induced in mice by administrering 1.5% DSS in their drinking water for 7 days. Mice were randomly divided into five different groups: DSS only (DSS-treated control group), DSS-treated with L (L group), DSS-treated with AC-L (AC-L group), DSS-treated with EAC-L (EAC-L group), DSS-treated with intraperitoneal IFX (IP-IFX group), and DSS-treated with per-oral IFX (PO-IFX group). Mice in the L, AC-L, and EAC-L groups were orally administered nanocomposite carriers for 9 days, from day 0. The dose of nanocomposite carriers (10 mg/kg for all groups) was predetermined to have an optimal therapeutic effect. Mice received 4 mg/kg of IFX in 200 μL PBS daily by oral or intraperitoneal administration for nine consecutive days. The dose of IFX was determined to have an optimal therapeutic effect based on existing studies [48, 49]. Drinking water was replaced with pure water and maintained for 2 days. Changes in body weight, stool consistency, and presence of blood in the stool or at the anus were measured daily throughout the study period. Mice were sacrificed at day 12; spleen and colons were collected to assess the therapeutic efficacy of the nanocomposite carriers. Disease activity index (DAI) was evaluated using the summed score of three factors (weight loss, stool consistency, and bleeding) [50].

**DSS-induced colitis and the therapeutic effect of nanocomposite carriers-IFX conjugates**

To test the therapeutic effect of nanocomposite carriers loaded with IFX, colitis was induced in mice via the addition of 1.5% DSS to drinking water for 7 days. Drinking water was then replaced with pure water for 4 days. All mice were sacrificed on day 11. Mice were orally administered, 200 μL PBS, IFX-L (10 mg/kg), AC-IFX-L (10 mg/kg), EAC-IFX-L (10 mg/kg) or PO-IFX (10 mg/kg), once daily, from day 0 to day 8 (total 9 days). The dose of nanocomposite carriers and IFX was predetermined to have an optimal therapeutic effect [48, 49]. Flow cytometry, qRT-PCR, analysis of TNF-α by enzyme-linked immunosorbent assay (ELISA), and western blotting are described in the Supplementary Information.

**Histology**

Colon tissues were fixed in 10% neutral formalin and then embedded in paraffin. Tissues were stained by hematoxylin and eosin and periodic acid Schiff (PAS) staining. The severity of colitis was scored as described previously [51]. Goblet cell staining was scored from 0 to 3 (3, minimal, <20%; 2, mild, 21–35%; 1, moderate, 36–50%; 0, marked, >50%).

**Goblet cell counting**

Colonic tissue sections were processed with PAS staining. Stained goblet cells were counted per crypt. Maximum 52 and minimum 20 fully conserved crypts on each section were examined, and the average numbers were marked as a representative goblet cell count of each section.

**Statistical analysis**

The data were reported as mean and standard deviation. Comparison among groups was done by performing Student’s t-tests or one-way analysis of variance (ANOVA) followed by Dunnett post-test using
GraphPad Prism software (La Jolla, CA, USA). Results with a $p$ value < 0.05 were reported as statistically significant.

**Declarations**

**Acknowledgements**

The authors thank Medical Illustration & Design, part of the Medical Research Support Services of Yonsei University College of Medicine, for all artistic support related to this work.

**Author contributions**

JMK, DHK, SWK, SJL, and JHC contributed to the concept and design of the study. HJP and SYR contributed to the preparation and physicochemical analysis of liposome coating and the stability of liposomes and cargoes (BSA and IFX) in the simulated gastrointestinal tract. JMK, DHK, HWM, ISP, and MJS contributed to the performance of the experimental study, sample preparation, and analysis. JMK and DHK contributed to the performance and analysis of the qRT-PCR data, western blotting, and flow cytometry. JMK and DHK performed statistical analysis. All authors contributed to drafting the manuscript. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Funding**

This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0094).

**Availability of data and materials**

All data and material are included in the article and its additional files.

**Ethics approval and consent to participate**

Peripheral blood from patients with IBD was collected and analyzed after obtaining informed written consent according to the approval of the Institutional Review Board of Severance Hospital, Yonsei University (4-2020-0010). Animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Yonsei University Severance Hospital, Seoul, Korea (IACUC Approval No: 2018–0174). All methods were carried out in accordance with relevant guidelines and regulations.

**Consent for publication**

Not applicable.

**Competing Interest**
All the authors declare no competing interests. All inferences, opinions, and conclusions drawn in this article are those of the authors and do not reflect the opinions or policies of the data steward(s).

Author details

1 Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea; 2 Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; 3 Department of Integrated Bioscience and Biotechnology, Sejong University, 209 Neungdong-ro, Gwangjin-gu, Seoul, Korea; 4 Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea; 5 Department of Integrative Bioscience and Biotechnology, Institute of Anticancer Medicine Development, Sejong University, Seoul, 05006, Republic of Korea; 6 College of Pharmacy, Dongguk University-Seoul, Dongguk-ro-32, Ilsan-donggu, Goyang, Korea

References

1. Perrier C, de Hertogh G, Cremer J, Vermeire S, Rutgeerts P, Van Assche G, Szymkowski DE, Ceuppens JL: Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis 2013, 19:246-253.

2. Uhlig HH, Powrie F: Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease. Annu Rev Immunol 2018, 36:755-781.

3. Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, et al: Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages. Gastroenterology 2011, 141:2026-2038.

4. Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, et al: Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008, 118:2269-2280.

5. Ordas I, Mould DR, Feagan BG, Sandborn WJ: Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012, 91:635-646.

6. Levin AD, Wildenberg ME, van den Brink GR: Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis 2016, 10:989-997.

7. Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, et al: Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016, 65:408-414.

8. Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, et al: Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019, 17:285-310.

9. Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svastrom H, Caspersen S, Munkholm P, Hviid A, Jess T: Association between tumor necrosis factor-alpha antagonists and risk of cancer in
patients with inflammatory bowel disease. *Jama* 2014, **311**:2406-2413.

10. Colombel JF, Loftus EV, Jr., Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ: **The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.** *Gastroenterology* 2004, **126**:19-31.

11. Agarwal A, Kedia S, Jain S, Gupta V, Bopanna S, Yadav DP, Goyal S, Mouli VP, Dhingra R, Makharia G, Ahuja V: **High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India.** *Intest Res* 2018, **16**:588-598.

12. Kane SV, Chao J, Mulani PM: **Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.** *Advances in therapy* 2009, **26**:936-946.

13. Bozzuto G, Molinari A: **Liposomes as nanomedical devices.** *Int J Nanomedicine* 2015, **10**:975-999.

14. Zhang R, Qian J, Li X, Yuan Y: **Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes.** *Br J Ophthalmol* 2017, **101**:1731-1738.

15. Kim JH, Hong SS, Lee M, Lee EH, Rhee I, Chang SY, Lim SJ: **Krill Oil-Incorporated Liposomes As An Effective Nanovehicle To Ameliorate The Inflammatory Responses Of DSS-Induced Colitis.** *Int J Nanomedicine* 2019, **14**:8305-8320.

16. Yang L, Shao Y, Han HK: **Improved pH-dependent drug release and oral exposure of telmisartan, a poorly soluble drug through the formation of drug-aminoclay complex.** *Int J Pharm* 2014, **471**:258-263.

17. Kim SY, Lee SJ, Han HK, Lim SJ: **Aminoclay as a highly effective cationic vehicle for enhancing adenovirus-mediated gene transfer through nanobiohybrid complex formation.** *Acta Biomater* 2017, **49**:521-530.

18. Coco R, Plapied L, Pourcelle V, Jerome C, Brayden DJ, Schneider YJ, Preat V: **Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.** *Int J Pharm* 2013, **440**:3-12.

19. Kshirsagar SJ, Bhalekar MR, Patel JN, Mohapatra SK, Shewale NS: **Preparation and characterization of nanocapsules for colon-targeted drug delivery system.** *Pharm Dev Technol* 2012, **17**:607-613.

20. Bautzova T, Rabiskova M, Beduneau M, Pellequer Y, Lamprecht A: **Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis.** *Eur J Pharm Biopharm* 2012, **81**:379-385.

21. Karn PR, Vanić Z, Pepić I, Škalko-Basnet N: **Mucoadhesive liposomal delivery systems: the choice of coating material.** *Drug development and industrial pharmacy* 2011, **37**:482-488.

22. Zenewicz LA, Antov A, Flavell RA: **CD4 T-cell differentiation and inflammatory bowel disease.** *Trends Mol Med* 2009, **15**:199-207.

23. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A: **Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.** *Clinical and experimental immunology* 1993, **94**:174-181.

24. Lee SH, Kwon JE, Cho M-L: **Immunological pathogenesis of inflammatory bowel disease.** *Intestinal research* 2018, **16**:26-42.
25. Yang M, Zhang F, Yang C, Wang L, Sung J, Garg P, Zhang M, Merlin D: Oral Targeted Delivery by Nanoparticles Enhances Efficacy of an Hsp90 Inhibitor by Reducing Systemic Exposure in Murine Models of Colitis and Colitis-Associated Cancer. J Crohns Colitis 2020, 14:130-141.

26. Zhang M, Xu C, Liu D, Han MK, Wang L, Merlin D: Oral Delivery of Nanoparticles Loaded With Ginger Active Compound, 6-Shogaol, Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis. J Crohns Colitis 2018, 12:217-229.

27. Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK: Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 2013, 447:75-93.

28. McConnell EL, Liu F, Basit AW: Colonic treatments and targets: issues and opportunities. J Drug Target 2009, 17:335-363.

29. Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, et al: First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. The American journal of gastroenterology 2014, 109:1041-1051.

30. Barea MJ, Jenkins MJ, Lee YS, Johnson P, Bridson RH: Encapsulation of Liposomes within pH Responsive Microspheres for Oral Colonic Drug Delivery. International journal of biomaterials 2012, 2012:458712-458712.

31. Kim SY, Kwon WA, Shin SP, Seo HK, Lim SJ, Jung YS, Han HK, Jeong KC, Lee SJ: Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity. Drug Deliv 2018, 25:49-58.

32. Nugent SG, Kumar D, Rampton DS, Evans DF: Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001, 48:571-577.

33. Press AG, Hauptmann IA, Hauptmann L, Fuchs B, Fuchs M, Ewe K, Ramadori G: Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1998, 12:673-678.

34. Nguyen TX, Huang L, Liu L, Elamin Abdalla AM, Gauthier M, Yang G: Chitosan-coated nanoparticles for the oral delivery of berberine hydrochloride. Journal of Materials Chemistry B 2014, 2:7149-7159.

35. Hu S, Niu M, Hu F, Lu Y, Qi J, Yin Z, Wu W: Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm 2013, 441:693-700.

36. Capaldo CT, Nusrat A: Claudin switching: Physiological plasticity of the Tight Junction. Semin Cell Dev Biol 2015, 42:22-29.

37. Cornick S, Tawiah A, Chadee K: Roles and regulation of the mucus barrier in the gut. Tissue Barriers 2015, 3:e982426.

38. Maisel K, Ensign L, Reddy M, Cone R, Hanes J: Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. Journal of controlled release: official journal of the Controlled Release Society 2015, 197:48-57.
39. Kim HY, Cheon JH, Lee SH, Min JY, Back SY, Song JG, Kim DH, Lim SJ, Han HK: Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization. *J Nanobiotechnology* 2020, **18**:17.
40. Yamasaki M, Muraki Y, Nishimoto Y, Murakawa Y, Matsuo T: Fluorescence-labeled liposome accumulation in injured colon of a mouse model of T-cell transfer-mediated inflammatory bowel disease. *Biochem Biophys Res Commun* 2017, **494**:188-193.
41. Lacruz-Guzman D, Torres-Moreno D, Pedrero F, Romero-Cara P, Garcia-Tercero I, Trujillo-Santos J, Conesa-Zamora P: Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis. *Eur J Clin Pharmacol* 2013, **69**:431-438.
42. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. *Gut* 2002, **50**:206-211.
43. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel disease. *Gut* 2003, **52**:65-70.
44. Caprioli F, Bose F, Rossi RL, Petti L, Vigano C, Ciafardini C, Raeli L, Basilisco G, Ferrero S, Pagani M, et al: Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy. *Inflamm Bowel Dis* 2013, **19**:729-739.
45. Coccia M, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, Maloy KJ: IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. *J Exp Med* 2012, **209**:1595-1609.
46. Gálvez J: Role of Th17 Cells in the Pathogenesis of Human IBD. *ISRN inflammation* 2014, **2014**:928461-928461.
47. Hong SS, Kim SH, Lim SJ: Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes. *Int J Pharm* 2015, **483**:142-150.
48. Berlec A, Perse M, Ravnikar M, Lunder M, Erman A, Cerar A, Strukelj B: Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor alpha. *Int Immunopharmacol* 2017, **43**:219-226.
49. Lenzen H, Qian J, Manns MP, Seidler U, Jorns A: Restoration of mucosal integrity and epithelial transport function by concomitant anti-TNFalpha treatment in chronic DSS-induced colitis. *J Mol Med (Berl)* 2018, **96**:831-843.
50. Seo DH, Che X, Kwak MS, Kim S, Kim JH, Ma HW, Kim DH, Kim TI, Kim WH, Kim SW, Cheon JH: Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. *Sci Rep* 2017, **7**:851.
51. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M: Dextran sulfate sodium (DSS)-induced colitis in mice. *Curr Protoc Immunol* 2014, **104**:15.25.11-15.25.14.

**Figures**
Figure 1

Fig. 1

|        | FITC-BSA |        |        |
|--------|----------|--------|--------|
|        | Liposome | AC-L   | EAC-L  |
| size (nm) | 368 ± 19 | 395 ± 37 | 486 ± 23 |
| Zeta potential (mV) | -79.9 ± 0.6 | +12.6 ± 0.5 | -55.4 ± 0.2 |
| Encapsulated concentration (μg/mL) | 769 ± 16 | -498 ± 86 | 338 ± 16 |

|        | Infliximab |        |        |
|--------|------------|--------|--------|
|        | Liposome   | AC-L   | EAC-L  |
| size (nm) | 244 ± 22 | 222 ± 14 | 426 ± 15 |
| Zeta potential (mV) | -54.0 ± 1.6 | +2.6 ± 0.2 | -31.5 ± 1.2 |
| Encapsulated concentration (μg/mL) | 2029 ± 224 | 1030 ± 71 | 636 ± 63 |
Characteristics of nanoparticles. (a) Transmission electron microscopy (TEM) images of fluorescein isothiocyanate (FITC)-bovine serum albumin (BSA) with nanocomposite carriers (liposome, aminoclay-coated, and Eudragit S100-clay-coated). Scale bar represents 50 µm. Liposomes were prepared with 40 µmole of DMPC:CHOL:DMPG:α-Tocopherol (26:10:2:2 molar ratio) and 10 mg of BSA-FITC per 1 mL. The zeta potential is the mean ± SD of two independent experiments (n = 2), and the size and captured concentration data are the mean ± SD of three independent experiments (n = 2) (b) TEM images of Eudragit S100-aminoclay-coated liposomes entrapped with infliximab (IFX). Scale bar represents 100 µm. Liposomes were prepared with 40 µmole of DMPC:CHOL:DMPG:α-Tocopherol (26:10:2:2 molar ratio) and 10 mg IFX per 1 mL. Size, zeta potential, and concentration of IFX encapsulated by nanocomposites were measured. AC-BSA-L, aminoclay-liposome-coated BSA; BSA, bovine serum albumin; BSA-L, liposome-coated BSA; EAC-IFX-L, Eudragit S100-liposome-coated IFX; Eudragit S100-aminoclay-liposome-coated IFX; FITC-BSA, BSA-fluorescein isothiocyanate conjugate (c) Time-dependent size changes of liposome, clay-liposome, and E100-clay-liposome incubated in PBS, SIF, or SGF at 37°C (d) Time-dependent fluorescein isothiocyanate-bovine serum albumin (FITC-BSA) release profile from liposomes incubated in phosphate-buffered saline (PBS) or simulated intestinal fluid (SIF, without pancreatin) at 37°C (e) Circular dichroism analysis of the BSA stability in the nanocomposites
Figure 2

Drug delivery formulations in vivo are effectively delivered to inflamed colon and do not have a systemic effect. Images were obtained 7 h after oral administration of Cy7-labeled delivery carriers using an in vivo imaging system (IVIS). (a) Fluorescence of Cy7 measured in the inflamed colon was observed in all drug delivery carrier groups. Arrows indicate strong fluorescence signals at the site of inflammation. (b) In inflamed small intestine, the AC-L group and EAC-L group were measured for fluorescence of Cy7. (c) Fluorescence images of Cy7 in a multi-well format obtained from organs (heart, lung, liver, spleen, pancreas, and kidney). (d) Average radiant efficiency of drug delivery formulations distributed in inflamed intestine in comparison to normal conditions. Data representative of eight independent groups with n = 3 mice/group (Vehicle group), n = 1 mice/group (Vehicle with Cy7 labeled L), n = 1 mice/group (Vehicle with Cy7 labeled AC-L), n = 3 mice/group (Vehicle with Cy7 labeled EAC-L), n = 2 mice/group (DSS colitis with vehicle), n = 2 mice/group (DSS colitis with Cy7 labeled L), n = 2 mice/group (DSS colitis with Cy7 labeled AC-L), n = 2 mice/group (DSS colitis with Cy7 labeled EAC-L). Data are expressed as means ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Statistical significance was assessed using Student's t-
test (d) and one-way ANOVA followed by Dunnett post-test. Control, treated with vehicle; DSS+Cy7_AC-L, DSS colitis with aminoclay-liposome-coated Cy7; DSS+Cy7_EAC-L, DSS colitis with Eudragit S100-liposome-coated Cy7; DSS+Cy7_L, DSS colitis with liposome-coated Cy7.

**Figure 3**

Drug delivery formulations in vitro are effectively delivered to lymphocytes and monocytes produced by the peripheral blood mononuclear cells of patients with ulcerative colitis (n = 4) and Crohn’s disease (n = 5). (a) Representative flow cytometry dot plot. Diagrams of flow cytometry gating the lymphocytes and monocytes of UC and CD patients. CD subset of T lymphocyte (CD3 and CD4) and macrophage (CD11b) in produced by peripheral blood mononuclear cells (PBMC) of IBD patients (b) median fluorescence intensities (MFIs) of BSA-FITC with drug delivery formulations between UC and CD patients. Data are expressed as means ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Statistical significance was assessed using Student’s t-test (d) and one-way ANOVA followed by Dunnett post-test. AC-L-FITC, aminoclay-liposome-coated FITC; BSA-FITC, bovine serum albumin-coated FITC; L-FITC, liposome-coated FITC; EAC-L-FITC, Eudragit S100-liposome-coated FITC.
Figure 4

Therapeutic effects of drug delivery formulations in mice with dextran sulfate sodium-induced colitis. (a) The methods for DSS-induced colitis and oral delivery carriers with infliximab (IFX) administration, control (n = 4), DSS only (n = 10), IFX-L group (n = 6), AC-IFX-L (n = 6), EAC-IFX-L (n = 10), PO-IFX (n = 8) (b) body weight changes of each group in DSS-induced colitis mouse model. (c) colon length; values are represented as length (cm). (d) the clinical activity scores in the control group and treatment groups measured using the disease activity index (DAI). (e) histopathologic features of nanocomposite carriers and IFX delivery formulations on the DSS-induced colitis mouse model, via PAS staining. Arrows indicate inflammatory cells in the lamina propria. Scale bar: 20 μm. Histomorphological scores and Goblet cell scores. Data are expressed as means ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Statistical significance was assessed using Student’s t-test (d) and one-way ANOVA followed by Dunnett post-test.
Figure 5

Anti-inflammatory effects of nanocomposite carriers loaded with IFX (a) Western blot analysis of protein expression of TNF-α and IL-1β in drug delivery formulations with IFX and their effects on the production and regulation of inflammation-related factors. The ratios to beta-actin to standardize cytokine protein expression in mice with DSS-induced colitis compared to control mice. (b) Expression of TNF-α in plasma of mice with DSS-induced colitis using ELISA. (c) Expression of inflammation-related cytokines mRNA levels in the colon of mice with colitis treated by IFX using drug delivery formulations. Gene expression were evaluated by quantitative RT-PCR and relative expression was reported as fold change compared to the control by normalizing transcription level to β-actin. Data are expressed as means ± SD. * p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Statistical significance was assessed using Student’s t-test (C-I) and one-way ANOVA followed by Dunnett post-test. AC-IFX-L, aminoclay-liposome-coated IFX; EAC-IFX-L, Eudragit S100-aminoclay-liposome-coated IFX; IFX, Infliximab; IFX-L, liposome-coated IFX; control, treated with vehicle.
Figure 6

A putative model for the distribution and interaction with T cells and macrophages of nanocomposite carriers in a colitis condition. Increased particle uptake due to epithelial leakage in colitis and infliximab (IFX) is active at the targeted colon: IFX reacts with macrophage and T cells in the colon to promote anti-inflammatory effects.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- s11.docx